Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | SVP, Chief Tech. Ops. Officer | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,341 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Exercise / conversion · Acquired 1,650 · Balance 20,341 F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 19,544 |
Reported balance
After 2026-08-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-12 · Tax withholding · Disposed 797 · Balance 19,544 F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 1,650 · Balance 0 F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · derivative · entry 7 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 750 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F5 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F5 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · nonDerivative · entry 4 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,024 Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · nonDerivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,774 Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Units · Derivative | 1,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · derivative · entry 6 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F3 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 552 | $39.15 | $21,610.80 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,024 F2 · price: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 21, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:57 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007194 · wk-form4_1740175057.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:57 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007194 · wk-form4_1740175057.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2026. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:35 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Units · Derivative | 2,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-006401 · wk-form4_1740000906.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625 Underlying: Common Stock · 2,625 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:57 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Units · Derivative | 2,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004278 · wk-form4_1738879018.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,010 Underlying: Common Stock · 2,010 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, portions of which vested upon the achievement of individual performance objectives within defined performance periods, which objectives were established on May 3, 2022. F2 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, portions of which vested upon the achievement of individual performance objectives within defined performance periods, which objectives were established on May 3, 2022. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:57 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004278 · wk-form4_1738879018.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 21:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Units · Derivative | 1,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-003012 · wk-form4_1738187944.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,125 Underlying: Common Stock · 1,125 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001628280-24-046668 · wk-form4_1731100428.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 3, 2016. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 15,000 | $36.98 | $554,700.00 |
DisclosureSEC source: 0001628280-24-046668 · wk-form4_1731100428.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 F2 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.73 to $37.27. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $9.13 | $136,950.00 |
DisclosureSEC source: 0001628280-24-046668 · wk-form4_1731100428.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 421 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 990 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-029434 · tm247055-37_4seq1.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022. F3 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F3 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 460 | $27.94 | $12,852.40 |
DisclosureSEC source: 0001104659-24-029434 · tm247055-37_4seq1.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,779 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-029434 · tm247055-37_4seq1.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028276 · tm247055-20_4seq1.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 1,875 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 937 | $29.06 | $27,229.22 |
DisclosureSEC source: 0001104659-24-028276 · tm247055-20_4seq1.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,249 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028276 · tm247055-20_4seq1.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,186 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 990 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027571 · tm247055-4_4seq1.xml · derivative · entry 6 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990 Underlying: Common Stock · 990 shares Expires not disclosed F7 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F7 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0001104659-24-027571 · tm247055-4_4seq1.xml · derivative · entry 5 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-02-22 F6 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027571 · tm247055-4_4seq1.xml · derivative · entry 4 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F5 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. F5 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027571 · tm247055-4_4seq1.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 750 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 335 | $27.94 | $9,359.90 |
DisclosureSEC source: 0001104659-24-027571 · tm247055-4_4seq1.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,311 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027571 · tm247055-4_4seq1.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,646 F1 · balance_after: Includes an aggregate of 215 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-23-119162 · tm2330879-1_4seq1.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on January 21, 2015. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 1,110 | $28.13 | $31,224.30 |
DisclosureSEC source: 0001104659-23-119162 · tm2330879-1_4seq1.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,681 F2 · shares: Represents the number of shares of common stock sold to cover the exercise price of the employee stock options. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 2,000 | $9.24 | $18,480.00 |
DisclosureSEC source: 0001104659-23-119162 · tm2330879-1_4seq1.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 343 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 4,780 | $35.99 | $172,022.64 |
DisclosureSEC source: 0001104659-23-033366 · tm239705-1_4seq1.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · Sr VP, Quality, GMP Oper. & IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,737 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.02. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026071 · tm237737-11_4seq1.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026071 · tm237737-11_4seq1.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025368 · tm237737-7_4seq1.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025368 · tm237737-7_4seq1.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,517 F1 · balance_after: Includes an aggregate of 576 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:00 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-044665 · tm2312277-3_4aseq.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · Sr VP, Quality, GMP Oper. & IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 750 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:00 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 289 | $38.57 | $11,146.73 |
DisclosureSEC source: 0001104659-23-044665 · tm2312277-3_4aseq.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · Sr VP, Quality, GMP Oper. & IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,228 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:00 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-044665 · tm2312277-3_4aseq.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · Sr VP, Quality, GMP Oper. & IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,517 F1 · balance_after: Includes an aggregate of 576 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:35 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-023877 · tm237193-1_4seq1.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:35 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 753 | $38.74 | $29,171.22 |
DisclosureSEC source: 0001104659-23-023877 · tm237193-1_4seq1.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,191 F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on April 30, 2021. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:35 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-023877 · tm237193-1_4seq1.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on April 30, 2021. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004292 · tm233672-3_4seq1.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 F1 · derivative.exercise_date: On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:26 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026881 · tm227622-9_4seq1.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:26 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026881 · tm227622-9_4seq1.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-02-22 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:15 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-027394 · tm227764-3_4aseq1.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: The option vests in four equal annual installments beginning on February 22, 2023. F4 · derivative.exercise_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. F4 · derivative.expiration_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:15 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-027394 · tm227764-3_4aseq1.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-02-22 F3 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026935 · tm217706-8_4seq1.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP Ops. & IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-02-19 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2022. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 23:51 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-20-024920 · a4.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · Sr VP, Quality, GMP Oper. & IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-02-21 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.